Store
Viral Vectors Market for Cell Therapy Market Analysis and Opportunities, 2021-2026
Publication Date: December 20, 2021
Tags: CAR-T Cell Therapy, Cardiovascular Disease, Cell and Gene Therapy, Genetic Diseases, Hematology, Infectious Diseases, Interventional Cardiology, Life Science, Oncology and Cancer
Pages: 105
SKU: 21-032
The viral vectors market is evolving with advancements in gene therapy and vaccine technologies. New developments are enabling viral vectors to produce stable, non-toxic, and safe therapeutic outcomes. As the industry moves towards standardized and automated manufacturing processes, the potential for viral vectors in treating cancers, genetic diseases, and other conditions continues to grow. Kalorama Information covers this market in the new report Viral Vectors Market for Cell Therapy Market Analysis and Opportunities, 2021-2026.
By the middle of the decade, viral vectors are expected to experience significant growth. This should not be surprising. Globally, millions of dollars are invested annually in viral vector technology for gene therapy and vaccines. In 2021, sales of viral vectors reached impressive figures, reflecting their crucial role in modern medicine. The rise of gene therapy and novel vaccine technologies has been a significant game changer in this market.
Updated for COVID-19 Impacts:
In some segments, COVID-19 caused a contraction due to lockdowns, closures, limited physician visits, and a reduction in elective and outpatient procedures. However, the market is expected to resume pre-pandemic growth across all segments. Certain areas will continue to advance significantly from 2021-2026. By 2026, the total global viral vectors market is projected to reach new heights, displaying robust growth over the forecast period.
Market Breakdown:
- Global Viral Vectors Market, 2021-2026 (in millions $ at manufacturer level)
- Global Viral Vectors Market Analysis by Product Category, 2021 (in millions $) (Gene Therapy, Vaccines, Total)
- Global Gene Therapy Viral Vectors Market Analysis by Product Category, 2021 (in millions $) (Retroviruses, Adenoviruses, Lentiviruses, Others, Total)
- Global Vaccine Viral Vectors Market Analysis by Product Category, 2021 (in millions $) (Adenoviruses, Poxviruses, Alphaviruses, Others, Total)
Regional Market Analysis:
The viral vectors market is also segmented by geographic region:
- Global Viral Vectors Market Analysis by Region/Country, 2021 (in millions $) (United States, Europe, Japan, ROW, Total)
- European Viral Vectors Market Analysis by Country, 2021 (in millions $) (Germany, UK, France, Italy, Others, Total)
- Asia-Pacific Viral Vectors Market Analysis by Country, 2021 (in millions $) (China, Japan, South Korea, India, Australia, Others, Total)
Segment Size and Growth:
Viral vector technology has significantly contributed to the growth of the overall gene therapy and vaccine markets over the past decade. More manufacturers are seeking regulatory approvals and expanding their capabilities. As new technologies emerge, viral vectors are expected to play an even more significant role in therapeutic development and patient care. The report provides an in-depth analysis of various market segments, including:
- Global Gene Therapy Viral Vectors Market Analysis, 2021-2026 (in millions $ at manufacturer level)
- Global Vaccine Viral Vectors Market Analysis, 2021-2026 (in millions $ at manufacturer level)
Scope and Methodology:
All market data are based on manufacturer sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers’ level. The base year for data was 2021 with forecast data provided for 2026. Compound annual growth rates (CAGRs) are provided for the 2021-2026 period for each segment covered. The forecasted market analysis is largely based on demographic trends, new developments, cell and gene therapy advancements, company performance trends, mergers and acquisitions, and global expansion.
For further details and to purchase directly, please contact us.
Table of Contents
CHAPTER 1: EXECUTIVE SUMMARY
OVERVIEW
SCOPE AND METHODOLOGY
MARKET TRENDS
MARKET DRIVERS AND LIMITERS
-
- Table 1-1: Viral Vector Market Drivers and Limiters
MARKET SUMMARY
-
- Table 1-2: Total Viral Vector Market Revenues 2021-2026 (in millions$)
-
- Figure 1-1: Viral Vector Market Revenues, 2021-2026 ($ millions)
COMPETITIVE LANDSCAPE
CHAPTER 2: INTRODUCTION TO VIRAL VECTORS
OVERVIEW
-
- Table 2-1: Selected Examples of Viruses in Gene Therapy
TYPES OF VIRAL VECTORS
- Retrovirus
- Adenovirus
- HSV Virus
- Chimeric Virus
- Other
DISEASE PROFILES IN VIRAL VECTOR MARKETS
- Cancer
- Figure 2-1: Incidence of Cancer by Type, 2020
- Figure 2-2: Distribution of Cancer Incidence by Type, 2020
- Cardiovascular Disease
- Selected Blood and Genetic Disorders
- Infectious Diseases
CHAPTER 3: MARKET TRENDS
POPULATION AND AGING
-
- Table 3-1: Elderly Support Ratio in Various Countries (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
ELDERLY POPULATION
-
- Figure 3-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
GENE THERAPY AND VIRAL VECTOR USE
CANCER AND VIRAL VECTOR USE
INFECTIOUS DISEASE AND VIRAL VECTOR USE
TRANSDUCTION AND TRANSFECTION
- Transfection
- Transduction
COMPETING METHODS
- Electroporation
- Non-Viral
- Transposons
VIRAL VECTOR SHORTAGES
COVID-19 PLATFORMS AND VACCINES
-
- Table 3-2: Selected Viral Vector-based COVID-19 Vaccines
PRODUCTS IN DEVELOPMENT UTILIZING VIRAL VECTORS
-
- Table 3-3: Selected Products in Development Utilizing Viral Vectors
CHAPTER 4: MARKET ANALYSIS
-
- Table 4-1: Total Viral Vector Market Revenues 2021-2026 (in millions$)
-
- Figure 4-1: Viral Vector Market Revenues, 2021-2026 ($ millions)
VIRAL VECTOR MARKET BY VECTOR TYPE
-
- Table 4-2: Viral Vector Market by Vector Type 2021-2026 (in millions)
-
- Figure 4-2: Viral Vector Market Percentage by Type 2021
-
- Figure 4-3: Viral Vector Market Percentage by Type 2026
VIRAL VECTOR MARKET SHARE BY DISEASE
-
- Figure 4-4: Viral Vector Market Percentage by Disease, 2021
VIRAL VECTOR USE BY APPLICATION
-
- Figure 4-5: Viral Vector Market Use Percentage by Application 2021
VIRAL VECTOR WORKFLOW PROCESSING
-
- Figure 4-6: Viral Vector Upstream/Downstream Workflow Percentage, 2021
-
- Figure 4-7: Viral Vector Upstream/Downstream Workflow Percentage, 2026
VIRAL VECTOR MARKET BY REGION
-
- Table 4-3: Global Viral Vector Market Revenues by Geographic Region, 2021-2026 (in millions$)
-
- Figure 4-8: Global Viral Vector Market Percent by Geographic Region, 2021
-
- Figure 4-9: Global Viral Vector Market Percent by Geographic Region, 2026
CHAPTER 5: COMPETITORS
COMPETITIVE LANDSCAPE
-
- Figure 5-1: Viral Vector Manufacturing – Pharmaceutical/Biotech companies vs CDMOs – 2021
ALLIANCES, ACQUISITIONS AND COLLABORATIONS
-
- Table 5-1: Selected Mergers and Acquisitions of Viral Vector Companies
EXPANSION OF MANUFACTURING
-
- Table 5-2: Selected Recent Viral Vector Company Expansion
COMPETITOR ANALYSIS
CHAPTER 6: MARKET PARTICIPANT PROFILES
4D MOLECULAR THERAPEUTICS, INC. (4DMT)
-
- Table 6-1: 4DMT Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-2: 4DMT (2019-2020) ($ thousands)
ABL INC
-
- Table 6-3: ABL Corporate Summary
- Company Overview
- Products
AGC BIOLOGICS
-
- Table 6-4: AGC Biologics Technologies Corporate Summary
- Company Overview
- Products
AGILENT TECHNOLOGIES
-
- Table 6-5: Agilent Technologies Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-6: Agilent (2017-2020) ($ millions)
ALDEVRON
-
- Table 6-7: Aldevron Corporate Summary
- Company Overview
- Products
BATAVIA BIOSCIENCES B.V.
-
- Table 6-8: Batavia Biosciences Corporate Summary
- Company Overview
- Products
BIOVIAN OY
-
- Table 6-9: Biovian Corporate Summary
- Company Overview
- Products
CATAPULT CELL AND GENE THERAPY
-
- Table 6-10: Catapult Cell and Gene Therapy Corporate Summary
- Company Overview
- Products
CEVEC PHARMACEUTICALS GMBH
-
- Table 6-11: Cevec Pharmaceuticals Corporate Summary
- Company Overview
- Products
COBRA BIOLOGICS
-
- Table 6-12: Cobra Biologics Corporate Summary
- Company Overview
- Products
CYTIVA LIFE SCIENCES
-
- Table 6-13: Cytiva Corporate Summary
- Company Overview
- Products
GENEZEN
-
- Table 6-14: Genezen Corporate Summary
- Company Overview
- Products
HORIZON DISCOVERY LTD.
-
- Table 6-15: Horizon Discovery Corporate Summary
- Company Overview
- Products
FINVECTOR OY
-
- Table 6-16: FinVector Corporate Summary
- Company Overview
- Products
FUJIFILM DIOSYNTH BIOTECHNOLOGIES
-
- Table 6-17: FUJIFILM Diosynth Corporate Summary
- Company Overview
- Products
LONZA
-
- Table 6-18: Lonza Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-19: Lonza (2019-2020) ($ millions)
MERCK KGAA/ MILLIPORE SIGMA
-
- Table 6-20: Millipore Sigma Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-21: Merck/MilliporeSigma (2019-2020) ($ millions)
MIRUS BIO
-
- Table 6-22: Mirus Bio Corporate Summary
- Company Overview
- Products
OXFORD BIOMEDICA PLC.
-
- Table 6-23: Agilent Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-24: Oxford Biomedica (2019-2020) ($ millions)
REGENXBIO, INC
-
- Table 6-25: REGENXBIO Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-26: REGENXBIO (2019-2020) ($ thousands)
SANOFI S.A.
-
- Table 6-27: Sanofi S.A. Corporate Summary
- Company Overview
- Products
SIRION BIOTECH
-
- Table 6-28: SIRION Biotech Corporate Summary
- Company Overview
- Products
SPARK THERAPEUTICS, INC
-
- Table 6-29: Spark Therapeutics Corporate Summary
- Company Overview
- Products
TAKARA BIO
-
- Table 6-30: Takara Bio Corporate Summary
- Company Overview
- Products
THERMO FISHER SCIENTIFIC
-
- Table 6-31: Thermo Fisher Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-32: Thermo Fisher Scientific (2019-2020) ($ millions)
UNIQURE N.V.
-
- Table 6-33: uniQure Corporate Summary
- Company Overview
- Products
- Performance Review
- Table 6-34: uniQure (2019-2020) ($ thousands)
VECTOR BIOLABS
-
- Table 6-35: Vector Biolabs Corporate Summary
- Company Overview
- Products
VIGENE BIOSCIENCES
-
- Table 6-36: Vigene Biosciences Corporate Summary
- Company Overview
- Products
VIROCELL BIOLOGICS
-
- Table 6-37: ViroCell Biologics Corporate Summary
- Company Overview
- Products
VIROVEK
-
- Table 6-38: Virovek Corporate Summary
- Company Overview
- Products
VOYAGER THERAPEUTICS
-
- Table 6-39: Voyager Therapeutics Corporate Summary
- Company Overview
- Products
WAISMAN BIOMANUFACTURING
-
- Table 6-40: Waisman Biomanufacturing Corporate Summary
- Company Overview
- Products
YPOSKESI
-
- Table 6-41: Yposkesi Corporate Summary
- Company Overview
- Products
Related products
Histology and Cytology IVD Market Update, 2024
May 21, 2024
Histology and cytology have long been essential components of pathological laboratories, offering critical insights into cells, tissues, and organs. Through histopathological examinations, a variety of diseases, including cancer, can be accurately diagnosed. Physicians rely heavily on pathological information to determine treatment plans and prognoses.
Histology and Cytology IVD Market Update, 2024 provides an in-depth competitive analysis…
Price range: $5,000.00 through $7,875.00
Cell Therapy and Gene Therapy Disease Markets, 2023-2029
April 30, 2024
Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in…
Price range: $5,000.00 through $7,875.00
The IVD Market in South Korea, 2024
February 26, 2024
Gain valuable insights into South Korea’s in vitro diagnostics (IVD) market with Kalorama Information’s comprehensive report, The IVD Market in South Korea, 2024. We offer a detailed analysis of South Korea’s IVD revenues for 2023 and forecasts for 2028, segmented into key categories such as clinical chemistry, immunoassay, microbiology/molecular testing, point-of-care (POC),…
Price range: $5,000.00 through $7,875.00
